Agency Information Collection Activities: Proposed Collection; Comment Request, 2916-2918 [2023-00796]
Download as PDF
<![CDATA[
2916
Federal Register / Vol. 88, No. 11 / Wednesday, January 18, 2023 / Notices
TABLE III—TEST INFORMATION RECEIVED FROM 12/1/2022 TO 12/31/2022—Continued
Case No.
Received date
Type of test information
P–15–0443 .............
12/21/2022
P–22–0129 .............
12/14/2022
P–23–0030 .............
12/06/2022
Bacterial Reverse Mutation Test (OECD Test Guideline 471)
If you are interested in information
that is not included in these tables, you
may contact EPA’s technical
information contact or general
information contact as described under
FOR FURTHER INFORMATION CONTACT to
access additional non-CBI information
that may be available.
Authority: 15 U.S.C. 2601 et seq.
Dated: January 12, 2023.
Pamela Myrick,
Director, Project Management and Operations
Division, Office of Pollution Prevention and
Toxics.
[FR Doc. 2023–00859 Filed 1–17–23; 8:45 am]
BILLING CODE 6560–50–P
FEDERAL ELECTION COMMISSION
Sunshine Act Meetings
FEDERAL REGISTER CITATION NOTICE OF
PREVIOUS ANNOUNCEMENT: 88 FR 863.
PREVIOUSLY ANNOUNCED TIME AND DATE OF
THE MEETING: Tuesday, January 10, 2023
at 10:00 a.m. and its continuation at the
conclusion of the open meeting on
January 12, 2023.
The meeting
began at 10:30 a.m. on January 10, 2023.
The meeting also discussed:
Matters relating to internal personnel
decisions, or internal rules and
practices.
*
*
*
*
*
CHANGES IN THE MEETING:
Judith
Ingram, Press Officer, Telephone: (202)
694–1220.
lotter on DSK11XQN23PROD with NOTICES1
FOR MORE INFORMATION CONTACT:
(Authority: Government in the Sunshine Act,
5 U.S.C. 552b)
Vicktoria J. Allen,
Acting Deputy Secretary of the Commission.
[FR Doc. 2023–00905 Filed 1–13–23; 11:15 am]
BILLING CODE 6715–01–P
VerDate Sep<11>2014
17:41 Jan 17, 2023
Chemical substance
90-Day Inhalation Toxicity Testing (OECD Test Guideline
413).
Water Solubility: Column Elution Method; Shake Flask Method (OECD Test Guideline 105).
Jkt 259001
(G) Rare earth doped zirconium oxide.
(G) Substituted heterocyclic onium compound, salt with
heteropolysubstitutedalkyl substitutedtricycloalkane
carboxylate (1:1), polymer with 1-alkenyl-4-[(alkylcycloalkyl)
oxy]carbomonocycle, 5-ethyloctahydro-4,7-methano-1hinden-5-yl 2-methyl-2-propenoate, hexahydro-5-oxo-2,6methanofuro[3,2-b]furan-3-yl 2-methyl-2-propenoate and 4hydroxyphenyl 2-methyl-2-propenoate.
(G) Phenol, polyalkylcarbo bis-, polymer with 2-carbomono
cyclichaloheteromonocycle, bis[(alkenylcarbomonocyclic)
alkyl] ether.
FEDERAL RESERVE SYSTEM
Formations of, Acquisitions by, and
Mergers of Bank Holding Companies
The companies listed in this notice
have applied to the Board for approval,
pursuant to the Bank Holding Company
Act of 1956 (12 U.S.C. 1841 et seq.)
(BHC Act), Regulation Y (12 CFR part
225), and all other applicable statutes
and regulations to become a bank
holding company and/or to acquire the
assets or the ownership of, control of, or
the power to vote shares of a bank or
bank holding company and all of the
banks and nonbanking companies
owned by the bank holding company,
including the companies listed below.
The public portions of the
applications listed below, as well as
other related filings required by the
Board, if any, are available for
immediate inspection at the Federal
Reserve Bank(s) indicated below and at
the offices of the Board of Governors.
This information may also be obtained
on an expedited basis, upon request, by
contacting the appropriate Federal
Reserve Bank and from the Board’s
Freedom of Information Office at
https://www.federalreserve.gov/foia/
request.htm. Interested persons may
express their views in writing on the
standards enumerated in the BHC Act
(12 U.S.C. 1842(c)).
Comments regarding each of these
applications must be received at the
Reserve Bank indicated or the offices of
the Board of Governors, Ann E.
Misback, Secretary of the Board, 20th
Street and Constitution Avenue NW,
Washington, DC 20551–0001, not later
than February 17, 2023.
A. Federal Reserve Bank of Atlanta
(Erien O. Terry, Assistant Vice
President) 1000 Peachtree Street NE,
Atlanta, Georgia 30309 or electronically
to Applications.Comments@atl.frb.org:
1. TIAA FSB Holdings, Inc.; to become
a bank holding company upon the
conversion of its subsidiary, TIAA, FBS,
both of Jacksonville, Florida, into a
national bank.
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
Board of Governors of the Federal Reserve
System.
Michele Taylor Fennell,
Deputy Associate Secretary of the Board.
[FR Doc. 2023–00857 Filed 1–17–23; 8:45 am]
BILLING CODE P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency for Healthcare Research and
Quality
Agency Information Collection
Activities: Proposed Collection;
Comment Request
Agency for Healthcare Research
and Quality, HHS.
ACTION: Notice.
AGENCY:
This notice announces the
intention of the Agency for Healthcare
Research and Quality (AHRQ) to request
that the Office of Management and
Budget (OMB) approve the proposed
information collection project
‘‘Supporting and Evaluating the
Dissemination and Implementation of
PCOR to Improve Non-Surgical
Treatment of Urinary Incontinence
Among Women in Primary Care.’’ This
proposed information collection was
previously published in the Federal
Register on October 28, 2022 and
allowed 60 days for public comment.
AHRQ received no substantive
comments. The purpose of this notice is
to allow an additional 30 days for public
comment.
DATES: Comments on this notice must be
received by February 17, 2023.
ADDRESSES: Written comments and
recommendations for the proposed
information collection should be sent
within 30 days of publication of this
notice to www.reginfo.gov/public/do/
PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function.
SUMMARY:
E:\FR\FM\18JAN1.SGM
18JAN1
2917
Federal Register / Vol. 88, No. 11 / Wednesday, January 18, 2023 / Notices
FOR FURTHER INFORMATION CONTACT:
Doris Lefkowitz, AHRQ Reports
Clearance Officer, (301) 427–1477, or by
email at doris.lefkowitz@AHRQ.hhs.gov.
SUPPLEMENTARY INFORMATION:
Proposed Project
Supporting and Evaluating the
Dissemination and Implementation of
PCOR To Improve Non-Surgical
Treatment of Urinary Incontinence
Among Women in Primary Care
AHRQ’s Improve Non-surgical
Treatment of Urinary Incontinence
Among Women in Primary Care
(INTUIT–PC) initiative, now named the
Managing Urinary Incontinence (MUI)
initiative, addresses important gaps in
urinary incontinence (UI) care for
women in the primary care setting. As
part of the MUI initiative, AHRQ is
funding five cooperative agreement
(U18) grantees to develop primary care
extension services to disseminate and
implement improved nonsurgical
treatment of UI for women—including
screening, diagnosis, management, and
specialty referral—within primary care
practices in separate regions of the
United States.
AHRQ is also conducting a project to
support the MUI cooperative agreements
and evaluate the initiative, which
includes:
• Support of the five U18 MUI
cooperative agreements in the form of a
learning community, technical
assistance, and other resources to assist
grantees to disseminate and implement
patient centered outcomes research
(PCOR) for nonsurgical treatment of
urinary incontinence for women in
primary care.
• A rigorous mixed methods process
and outcome evaluation of the grantees’
dissemination and implementation
strategies.
This evaluation is being conducted by
AHRQ through its contractor, RAND,
pursuant to AHRQ’s authority to carry
out the PCOR dissemination activities
described in section 937 of the Public
Health Service Act. 42 U.S.C. 299b–37.
Method of Collection
To achieve the goals of this multisite
evaluation, AHRQ is requesting OMB
approval for three years of data
collection by the evaluator. The
evaluator’s primary data collection is
requested to achieve the goals of the
multisite evaluation and includes the
following data collection activities:
(1) Focus groups with practice
facilitators who are employed by the
MUI U18 grantees to provide direct
technical assistance to primary care
practices.
(2) Semi-structured interviews with
leaders and staff of primary care
practices participating in the MUI U18
studies.
Practice facilitator focus groups.
Practice facilitators (also known as
practice coaches) perform a critical role
in enabling primary care practices to
implement evidence-based
improvements. The purpose of the
annual focus groups with practice
facilitators is to gather their insights on
challenges assisting various types of
primary care practices, the resources
needed to promote improvement in
primary care practices, and the
effectiveness of different dissemination
and implementation strategies used by
the MUI U18 studies. The evaluator
aims to conduct a virtual focus group
with 8–10 practice facilitators for each
of the five U18 studies, for an expected
total of 45 focus group participants per
year.
Practice leader/staff semi-structured
interviews. The goal of the MUI U18
studies is to disseminate and implement
evidence-based UI treatment for women
within primary care practices. The
purpose of the semi-structured
interviews with leaders and staff of
primary care practices is to collect data
from the practices’ perspective on the
barriers and facilitators to implementing
evidence-based UI treatment for women
in primary care, as well as on the utility
of the technical assistance and resources
provided to practices by the grant
studies. The evaluator aims to conduct
4–8 in-person individual interviews in
one practice per each U18 study
(average of 1 interviews × on average 6
participants × 1 practice × 5 grants = 30
interviews), and 1 telephone interview
with 1–2 participants per interview for
two additional practices per each grant
study (1 interview × on average 1.5
participants × 2 practices × 5 grants = 15
interviews), for an expected total of 45
interview participants per year.
Estimated Annual Respondent Burden
Exhibit A.1a shows the estimated
annualized burden hours for the
respondents’ time to complete the
Practice Facilitator Focus Groups and
Practice Leader/Staff Semi-Structured
Interviews. For the three-year clearance
period, the estimated annualized burden
hours for the interviews are $2,190.50.
EXHIBIT A.1a—ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Form name
Number of
responses per
respondent
Hours per
response
Total burden
hours
Practice Facilitator Focus Groups ...................................................................
Practice Leader/Staff Semi-Structured Interviews ...........................................
45
45
1
1
1
1
45
45
Total ..........................................................................................................
90
N/A
N/A
90
EXHIBIT A.1b—ESTIMATED ANNUALIZED COST BURDEN
Number of
respondents
lotter on DSK11XQN23PROD with NOTICES1
Form name
Total burden
hours
Average
hourly wage
rate *
Total cost
burden
Practice Facilitator Focus Groups ...................................................................
Practice Leader/Staff Semi-Structured Interviews ...........................................
45
45
45
45
a $28.01
a 28.01
1,260.45
1,260.45
Total ..........................................................................................................
90
90
24.34
2,520.90
* Mean hourly wage for All Occupations (00–0000).
a Occupational Employment Statistics, May 2021 National Occupational Employment and Wage Estimates United States, U.S. Department of
Labor, Bureau of Labor Statistics.
VerDate Sep<11>2014
17:41 Jan 17, 2023
Jkt 259001
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
E:\FR\FM\18JAN1.SGM
18JAN1
2918
Federal Register / Vol. 88, No. 11 / Wednesday, January 18, 2023 / Notices
Request for Comments
In accordance with the Paperwork
Reduction Act, 44 U.S.C. 3501–3520,
comments on AHRQ’s information
collection are requested with regard to
any of the following: (a) whether the
proposed collection of information is
necessary for the proper performance of
AHRQ’s health care research and health
care information dissemination
functions, including whether the
information will have practical utility;
(b) the accuracy of AHRQ’s estimate of
burden (including hours and costs) of
the proposed collection(s) of
information; (c) ways to enhance the
quality, utility and clarity of the
information to be collected; and (d)
ways to minimize the burden of the
collection of information upon the
respondents, including the use of
automated collection techniques or
other forms of information technology.
Comments submitted in response to
this notice will be summarized and
included in the Agency’s subsequent
request for OMB approval of the
proposed information collection. All
comments will become a matter of
public record.
Dated: January 11, 2023.
Marquita Cullom,
Associate Director.
[FR Doc. 2023–00796 Filed 1–17–23; 8:45 am]
BILLING CODE 4160–90–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency for Toxic Substances and
Disease Registry
[30Day–23–0041]
lotter on DSK11XQN23PROD with NOTICES1
Agency Forms Undergoing Paperwork
Reduction Act Review
In accordance with the Paperwork
Reduction Act of 1995, the Agency for
Toxic Substances and Disease Registry
(ATSDR) has submitted the information
collection request titled the ‘‘National
Amyotrophic Lateral Sclerosis (ALS)
Registry’’ to the Office of Management
and Budget (OMB) for review and
approval. ATSDR previously published
a ‘‘Proposed Data Collection Submitted
for Public Comment and
Recommendations’’ notice on
September 30, 2022, to obtain comments
from the public and affected agencies.
ATSDR received one comment related
to the previous notice. This notice
serves to allow an additional 30 days for
public and affected agency comments.
ATSDR will accept all comments for
this proposed information collection
project. The Office of Management and
VerDate Sep<11>2014
17:41 Jan 17, 2023
Jkt 259001
Budget is particularly interested in
comments that:
(a) Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
(b) Evaluate the accuracy of the
agencies estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and
clarity of the information to be
collected;
(d) Minimize the burden of the
collection of information on those who
are to respond, including, through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses; and
(e) Assess information collection
costs.
To request additional information on
the proposed project or to obtain a copy
of the information collection plan and
instruments, call (404) 639–7570.
Comments and recommendations for the
proposed information collection should
be sent within 30 days of publication of
this notice to www.reginfo.gov/public/
do/PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function. Direct written
comments and/or suggestions regarding
the items contained in this notice to the
Attention: CDC Desk Officer, Office of
Management and Budget, 725 17th
Street NW, Washington, DC 20503 or by
fax to (202) 395–5806. Provide written
comments within 30 days of notice
publication.
Proposed Project
National Amyotrophic Lateral
Sclerosis (ALS) Registry (OMB Control
No. 0923–0041, Exp. 1/31/2023)—
Revision—Agency for Toxic Substances
and Disease Registry (ATSDR).
Background and Brief Description
The Agency for Toxic Substances and
Disease Registry (ATSDR) is requesting
a three-year Paperwork Reduction Act
(PRA) clearance for a revision
information collection request (ICR)
titled the ‘‘National Amyotrophic
Lateral Sclerosis (ALS) Registry’’ (OMB
Control No. 0923–0041, Exp. Date 01/
31/2023).
In 2008, Public Law 110–373 (the ALS
Registry Act) amended the Public
Health Service Act for ATSDR to: (1)
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
develop a system to collect data ALS
and other motor neuron disorders that
can be confused with ALS,
misdiagnosed as ALS, or progress to
ALS; and (2) establish a national registry
for the collection and storage of such
data to develop a population-based
registry of cases. Under these two
mandates, ATSDR established the
National ALS Registry.
The primary operational goal of the
Registry is to obtain reliable information
on the incidence and prevalence of ALS,
and to better describe the demographic
characteristics (age, race, sex, and
geographic location) of persons with
ALS. The secondary operational goal of
the surveillance system/registry is to
collect additional information on
potential risk factors for ALS, including,
but not limited to, family history of
ALS, smoking history, military service,
residential history, lifetime
occupational exposure, home pesticide
use, hobbies, participation in sports,
hormonal and reproductive history
(women only), caffeine use, trauma,
health insurance, open-ended
supplemental questions, and clinical
signs and symptoms.
With those goals in mind, persons
with ALS first joined the Registry in
2010. Those interested in taking part
answered a series of validation
questions. If determined to be eligible,
they created an online account to enroll
in the Registry. Next, they were asked to
complete up to 17 one-time voluntary
survey modules, each taking up to five
minutes. New registrants were also
asked to complete a longitudinal disease
progression survey (modified from the
ALS Functional Rating Scale—Revised
[ALSFRS–R]) at regular intervals over
their first three years in the Registry.
A biorepository component was
added in 2016. At the time of
enrollment, interested registrants can
request additional information about the
biorepository and provide additional
contact information. ATSDR selects a
geographically representative sample
from among the interested registrants to
collect specimens. There are two types
of specimen collections, in-home and
postmortem. The in-home collection
includes blood, urine, hair, nails, and
saliva. The postmortem collection
includes the brain, spinal cord, cerebral
spinal fluid (CSF), bone, muscle, and
skin. Researchers can now request
access to registrants’ specimens, data, or
both through an ATSDR research
application process. Once approved for
scientific merit, validity, and human
subjects protections, ATSDR makes the
requested data and/or specimens
available to the requester. ATSDR also
collaborates with ALS service
E:\FR\FM\18JAN1.SGM
18JAN1
]]>Agencies
[Federal Register Volume 88, Number 11 (Wednesday, January 18, 2023)]
[Notices]
[Pages 2916-2918]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-00796]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Agency for Healthcare Research and Quality
Agency Information Collection Activities: Proposed Collection;
Comment Request
AGENCY: Agency for Healthcare Research and Quality, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This notice announces the intention of the Agency for
Healthcare Research and Quality (AHRQ) to request that the Office of
Management and Budget (OMB) approve the proposed information collection
project ``Supporting and Evaluating the Dissemination and
Implementation of PCOR to Improve Non-Surgical Treatment of Urinary
Incontinence Among Women in Primary Care.'' This proposed information
collection was previously published in the Federal Register on October
28, 2022 and allowed 60 days for public comment. AHRQ received no
substantive comments. The purpose of this notice is to allow an
additional 30 days for public comment.
DATES: Comments on this notice must be received by February 17, 2023.
ADDRESSES: Written comments and recommendations for the proposed
information collection should be sent within 30 days of publication of
this notice to www.reginfo.gov/public/do/PRAMain. Find this particular
information collection by selecting ``Currently under 30-day Review--
Open for Public Comments'' or by using the search function.
[[Page 2917]]
FOR FURTHER INFORMATION CONTACT: Doris Lefkowitz, AHRQ Reports
Clearance Officer, (301) 427-1477, or by email at
[email protected].
SUPPLEMENTARY INFORMATION:
Proposed Project
Supporting and Evaluating the Dissemination and Implementation of PCOR
To Improve Non-Surgical Treatment of Urinary Incontinence Among Women
in Primary Care
AHRQ's Improve Non-surgical Treatment of Urinary Incontinence Among
Women in Primary Care (INTUIT-PC) initiative, now named the Managing
Urinary Incontinence (MUI) initiative, addresses important gaps in
urinary incontinence (UI) care for women in the primary care setting.
As part of the MUI initiative, AHRQ is funding five cooperative
agreement (U18) grantees to develop primary care extension services to
disseminate and implement improved nonsurgical treatment of UI for
women--including screening, diagnosis, management, and specialty
referral--within primary care practices in separate regions of the
United States.
AHRQ is also conducting a project to support the MUI cooperative
agreements and evaluate the initiative, which includes:
Support of the five U18 MUI cooperative agreements in the
form of a learning community, technical assistance, and other resources
to assist grantees to disseminate and implement patient centered
outcomes research (PCOR) for nonsurgical treatment of urinary
incontinence for women in primary care.
A rigorous mixed methods process and outcome evaluation of
the grantees' dissemination and implementation strategies.
This evaluation is being conducted by AHRQ through its contractor,
RAND, pursuant to AHRQ's authority to carry out the PCOR dissemination
activities described in section 937 of the Public Health Service Act.
42 U.S.C. 299b-37.
Method of Collection
To achieve the goals of this multisite evaluation, AHRQ is
requesting OMB approval for three years of data collection by the
evaluator. The evaluator's primary data collection is requested to
achieve the goals of the multisite evaluation and includes the
following data collection activities:
(1) Focus groups with practice facilitators who are employed by the
MUI U18 grantees to provide direct technical assistance to primary care
practices.
(2) Semi-structured interviews with leaders and staff of primary
care practices participating in the MUI U18 studies.
Practice facilitator focus groups. Practice facilitators (also
known as practice coaches) perform a critical role in enabling primary
care practices to implement evidence-based improvements. The purpose of
the annual focus groups with practice facilitators is to gather their
insights on challenges assisting various types of primary care
practices, the resources needed to promote improvement in primary care
practices, and the effectiveness of different dissemination and
implementation strategies used by the MUI U18 studies. The evaluator
aims to conduct a virtual focus group with 8-10 practice facilitators
for each of the five U18 studies, for an expected total of 45 focus
group participants per year.
Practice leader/staff semi-structured interviews. The goal of the
MUI U18 studies is to disseminate and implement evidence-based UI
treatment for women within primary care practices. The purpose of the
semi-structured interviews with leaders and staff of primary care
practices is to collect data from the practices' perspective on the
barriers and facilitators to implementing evidence-based UI treatment
for women in primary care, as well as on the utility of the technical
assistance and resources provided to practices by the grant studies.
The evaluator aims to conduct 4-8 in-person individual interviews in
one practice per each U18 study (average of 1 interviews x on average 6
participants x 1 practice x 5 grants = 30 interviews), and 1 telephone
interview with 1-2 participants per interview for two additional
practices per each grant study (1 interview x on average 1.5
participants x 2 practices x 5 grants = 15 interviews), for an expected
total of 45 interview participants per year.
Estimated Annual Respondent Burden
Exhibit A.1a shows the estimated annualized burden hours for the
respondents' time to complete the Practice Facilitator Focus Groups and
Practice Leader/Staff Semi-Structured Interviews. For the three-year
clearance period, the estimated annualized burden hours for the
interviews are $2,190.50.
Exhibit A.1a--Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Number of
Form name Number of responses per Hours per Total burden
respondents respondent response hours
----------------------------------------------------------------------------------------------------------------
Practice Facilitator Focus Groups............... 45 1 1 45
Practice Leader/Staff Semi-Structured Interviews 45 1 1 45
---------------------------------------------------------------
Total....................................... 90 N/A N/A 90
----------------------------------------------------------------------------------------------------------------
Exhibit A.1b--Estimated Annualized Cost Burden
----------------------------------------------------------------------------------------------------------------
Number of Total burden Average hourly Total cost
Form name respondents hours wage rate * burden
----------------------------------------------------------------------------------------------------------------
Practice Facilitator Focus Groups............... 45 45 \a\ $28.01 1,260.45
Practice Leader/Staff Semi-Structured Interviews 45 45 \a\ 28.01 1,260.45
---------------------------------------------------------------
Total....................................... 90 90 24.34 2,520.90
----------------------------------------------------------------------------------------------------------------
* Mean hourly wage for All Occupations (00-0000).
\a\ Occupational Employment Statistics, May 2021 National Occupational Employment and Wage Estimates United
States, U.S. Department of Labor, Bureau of Labor Statistics.
[[Page 2918]]
Request for Comments
In accordance with the Paperwork Reduction Act, 44 U.S.C. 3501-
3520, comments on AHRQ's information collection are requested with
regard to any of the following: (a) whether the proposed collection of
information is necessary for the proper performance of AHRQ's health
care research and health care information dissemination functions,
including whether the information will have practical utility; (b) the
accuracy of AHRQ's estimate of burden (including hours and costs) of
the proposed collection(s) of information; (c) ways to enhance the
quality, utility and clarity of the information to be collected; and
(d) ways to minimize the burden of the collection of information upon
the respondents, including the use of automated collection techniques
or other forms of information technology.
Comments submitted in response to this notice will be summarized
and included in the Agency's subsequent request for OMB approval of the
proposed information collection. All comments will become a matter of
public record.
Dated: January 11, 2023.
Marquita Cullom,
Associate Director.
[FR Doc. 2023-00796 Filed 1-17-23; 8:45 am]
BILLING CODE 4160-90-P
